OLX-101A is under clinical development by OliX Pharmaceuticals and currently in Phase II for Hypertrophic Scars. According to GlobalData, Phase II drugs for Hypertrophic Scars does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the OLX-101A LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OLX-101A overview

OLX-101A (BMT-101) is under development for the treatment of hypertrophic scar. It is administered topically, intradermally and through subcutaneous routes. The drug candidate is a second generation siRNA which that acts by targeting connective tissue growth factor genes. It is based on the cp-lasiRNA technology.

The drug candidate was also under development for the treatment of idiopathic pulmonary fibrosis and senile (age related) macular degeneration.

OliX Pharmaceuticals overview

OliX Pharmaceuticals a clinical-stage biotechnology company that carries out the discovery and development of RNA interference (RNAi) therapeutics. The company’s pipeline products include OLX101A, to treat skin scars; OLX104C, to treat androgenic alopecia; OLX401A, to treat neuropathic pain; OLX301D, to treat subretinal fibrosis; OLX801A to treat cancer immunotherapy and OLX402 to treat brain disease, among others. It utilizes Small interfering RNA (siRNA), lasiRNA, cp-asiRNA, tiRNA and bg-asiRNA technologies for developing lead products. Olix Pharmaceuticals collaborates with Hugel Inc; Hansoh Pharmaceuticals Group Co Ltd; Charles River Laboratories; and Korea Institute of Toxicology, Department of Inhalation Research, among others. The company operates in South Korea and the US. Olix Pharmaceuticals is headquartered in Suwon, South Korea.

For a complete picture of OLX-101A’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.